StockNews.AI
ABSI
StockNews.AI
168 days

Absci to Participate in the KeyBanc Capital Markets Healthcare Forum

1. Absci to attend KeyBanc Healthcare Forum on March 19, 2025. 2. Management will conduct a fireside chat during the event. 3. Absci specializes in AI-driven drug creation technologies. 4. The Integrated Drug Creation™ platform enhances drug development speed. 5. The company validates candidates quickly, within six weeks.

3m saved
Insight
Article

FAQ

Why Bullish?

Participation in a major healthcare forum may positively influence investor confidence. Previous similar events have led to price increases for biotech companies.

How important is it?

The announcement strengthens investor awareness and may lead to increased engagement in the stock.

Why Short Term?

The information about the upcoming event will likely drive short-term investor interest and market reaction. Similar past events have produced immediate spikes in interest and investment.

Related Companies

NVAXMRNACRISARCT
March 04, 2025 08:00 ET  | Source: Absci Corporation VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming virtual KeyBanc Capital Markets Healthcare Forum. Absci management is scheduled to participate in a fireside chat on Wednesday, March 19th at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube. Investor ContactAlex KhanVP, Finance & Investor Relationsinvestors@absci.com Media Contactpress@absci.com

Related News